Dr Muhammad Waqar Rehan, Dr Ayesha Shaukat, Dr Muhammad Yasir
Introduction: Chronic liver disease (CLD) is a major cause of morbidity and mortality and is quickly becoming an increasing burden on the health care system. Both CLD and cirrhosis are the fifth leading cause of death in the 45–61 age group and 12th leading cause overall. Objective of the study: The main objective of the study is to analyze the liver function test (LFT’s) in hepatitis patients and role of interferon therapy as a progressive treatment in Pakistan. Methodology of the study: This cross sectional study was conducted at Shalamar Hospital, Lahore during January 2018 to November 2018. The data was collected from 200 patients of both genders who were suffering from hepatitis. The data was collected through a detailed questionnaire through which we collect the demographic data of patients. Blood investigation including Hemoglobin (Hb), total leucocytes count (TLC), differential leucocytes count (DLC), platelet count, X-ray chest, ultrasound abdomen and LFT were done in all patients. Results: The demographic values of patient group and control group shows a significant difference. The data suggest clearly that CD4 count decreases in abnormal liver function. There were non-significant relationship present in diseased group treated with different therapies like interferon and glutathione as p<0.05. The normal range of AST is 5–34 U/L. The AST values in the fibrosis stages 3 and 4 were significantly elevated when compared to stage 0. Conclusion: It is concluded that hepatitis directly increase the liver enzymes even after receiving medication and other therapies. With new and effective treatments becoming available for the treatment of liver disease, identification of such individuals with proper risk factor.